Impaired spontaneous thrombolytic activity measured by global thrombosis test in males with metabolic syndrome

Abstract

IntroductionIn patients with metabolic syndrome (MetS), activity of the fibrinolytic system is generally surmised to be decreased through increased plasminogen activator inhibitor-1 (PAI-1) generation. However, there have been no detailed reports describing whether the clot lysis activity is more dominant than increased clot formation activity for production of the thrombotic state in MetS. MethodsThe global thrombosis test (GTT) is a novel method designed to test both clot formation and clot lysis activities under physiological conditions by using non-anticoagulated blood samples in vitro. We used the GTT to examine the thrombotic or thrombolytic states in males with MetS. ResultsLysis time, which reflects spontaneous clot lysis activity, was significantly longer in MetS subjects (median, 1494s; range, 865–3596s; n=30) than in control subjects (median 1246s; range, 667–2239s; n=53). There was no significant difference between the two groups in occlusion time, which reflects platelet function. The mean level of PAI-1 was significantly higher in MetS subjects than in controls (mean±SE, 8.7±1.1 and 5.0±0.5ng/mL, respectively). PAI-1 level and lysis time were significantly correlated (r=0.400, P<0.01). ConclusionThese results suggest that male patients with MetS are more likely than controls to experience a thrombotic state through decreased fibrinolytic activity due to increased PAI-1 generation, and that the GTT is useful for evaluating fibrinolytic activity in vitro.